Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

SPARC is required for the maintenance of glucose homeostasis and insulin secretion in mice.

Atorrasagasti C, Onorato A, Gimeno ML, Andreone L, Garcia M, Malvicini M, Fiore E, Bayo J, Perone MJ, Mazzolini G.

Clin Sci (Lond). 2019 Jan 9. pii: CS20180714. doi: 10.1042/CS20180714. [Epub ahead of print]

PMID:
30626728
2.

4Mu Decreases CD47 Expression on Hepatic Cancer Stem Cells and Primes a Potent Antitumor T Cell Response Induced by Interleukin-12.

Rodríguez MM, Fiore E, Bayo J, Atorrasagasti C, García M, Onorato A, Domínguez L, Malvicini M, Mazzolini G.

Mol Ther. 2018 Dec 5;26(12):2738-2750. doi: 10.1016/j.ymthe.2018.09.012. Epub 2018 Sep 18.

PMID:
30301668
3.

SPARC expression is associated with hepatic injury in rodents and humans with non-alcoholic fatty liver disease.

Mazzolini G, Atorrasagasti C, Onorato A, Peixoto E, Schlattjan M, Sowa JP, Sydor S, Gerken G, Canbay A.

Sci Rep. 2018 Jan 15;8(1):725. doi: 10.1038/s41598-017-18981-9.

4.

Involvement of hepatic macrophages in the antifibrotic effect of IGF-I-overexpressing mesenchymal stromal cells.

Fiore E, Malvicini M, Bayo J, Peixoto E, Atorrasagasti C, Sierra R, Rodríguez M, Gómez Bustillo S, García MG, Aquino JB, Mazzolini G.

Stem Cell Res Ther. 2016 Nov 22;7(1):172.

5.

Tumor Microenvironment Remodeling by 4-Methylumbelliferone Boosts the Antitumor Effect of Combined Immunotherapy in Murine Colorectal Carcinoma.

Malvicini M, Fiore E, Ghiaccio V, Piccioni F, Rizzo M, Olmedo Bonadeo L, García M, Rodríguez M, Bayo J, Peixoto E, Atorrasagasti C, Alaniz L, Aquino J, Matar P, Mazzolini G.

Mol Ther. 2015 Sep;23(9):1444-55. doi: 10.1038/mt.2015.112. Epub 2015 Jun 24.

6.

4-methylumbelliferone inhibits hepatocellular carcinoma growth by decreasing IL-6 production and angiogenesis.

Piccioni F, Fiore E, Bayo J, Atorrasagasti C, Peixoto E, Rizzo M, Malvicini M, Tirado-González I, García MG, Alaniz L, Mazzolini G.

Glycobiology. 2015 Aug;25(8):825-35. doi: 10.1093/glycob/cwv023. Epub 2015 Apr 16.

PMID:
25882295
7.

SPARC (secreted protein acidic and rich in cysteine) knockdown protects mice from acute liver injury by reducing vascular endothelial cell damage.

Peixoto E, Atorrasagasti C, Aquino JB, Militello R, Bayo J, Fiore E, Piccioni F, Salvatierra E, Alaniz L, García MG, Bataller R, Corrales F, Gidekel M, Podhajcer O, Colombo MI, Mazzolini G.

Gene Ther. 2015 Jan;22(1):9-19. doi: 10.1038/gt.2014.102. Epub 2014 Nov 20.

8.

Mesenchymal stromal cells engineered to produce IGF-I by recombinant adenovirus ameliorate liver fibrosis in mice.

Fiore EJ, Bayo JM, Garcia MG, Malvicini M, Lloyd R, Piccioni F, Rizzo M, Peixoto E, Sola MB, Atorrasagasti C, Alaniz L, Camilletti MA, Enguita M, Prieto J, Aquino JB, Mazzolini G.

Stem Cells Dev. 2015 Mar 15;24(6):791-801. doi: 10.1089/scd.2014.0174. Epub 2014 Dec 3.

9.

Lack of the matricellular protein SPARC (secreted protein, acidic and rich in cysteine) attenuates liver fibrogenesis in mice.

Atorrasagasti C, Peixoto E, Aquino JB, Kippes N, Malvicini M, Alaniz L, Garcia M, Piccioni F, Fiore EJ, Bayo J, Bataller R, Guruceaga E, Corrales F, Podhajcer O, Mazzolini G.

PLoS One. 2013;8(2):e54962. doi: 10.1371/journal.pone.0054962. Epub 2013 Feb 11.

10.

Chemoimmunotherapy for advanced gastrointestinal carcinomas: A successful combination of gene therapy and cyclophosphamide.

Malvicini M, Piccioni F, Bayo J, Fiore E, Atorrasagasti C, Alaniz L, Garcia M, Aquino JB, Gidekel M, Matar P, Mazzolini G.

Oncoimmunology. 2012 Dec 1;1(9):1626-1628.

11.

Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice.

Malvicini M, Alaniz L, Bayo J, Garcia M, Piccioni F, Fiore E, Atorrasagasti C, Aquino JB, Matar P, Mazzolini G.

Oncoimmunology. 2012 Oct 1;1(7):1038-1047.

12.

Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice.

Piccioni F, Malvicini M, Garcia MG, Rodriguez A, Atorrasagasti C, Kippes N, Piedra Buena IT, Rizzo MM, Bayo J, Aquino J, Viola M, Passi A, Alaniz L, Mazzolini G.

Glycobiology. 2012 Mar;22(3):400-10. doi: 10.1093/glycob/cwr158. Epub 2011 Oct 28.

PMID:
22038477
13.

Low molecular weight hyaluronan preconditioning of tumor-pulsed dendritic cells increases their migratory ability and induces immunity against murine colorectal carcinoma.

Alaniz L, Rizzo M, Garcia MG, Piccioni F, Aquino JB, Malvicini M, Atorrasagasti C, Bayo J, Echeverria I, Sarobe P, Mazzolini G.

Cancer Immunol Immunother. 2011 Oct;60(10):1383-95. doi: 10.1007/s00262-011-1036-0. Epub 2011 Jun 3.

PMID:
21638126
14.

Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12.

Malvicini M, Ingolotti M, Piccioni F, Garcia M, Bayo J, Atorrasagasti C, Alaniz L, Aquino JB, Espinoza JA, Gidekel M, Scharovsky OG, Matar P, Mazzolini G.

Mol Oncol. 2011 Jun;5(3):242-55. doi: 10.1016/j.molonc.2011.03.007. Epub 2011 Apr 5.

15.

SPARC downregulation attenuates the profibrogenic response of hepatic stellate cells induced by TGF-β1 and PDGF.

Atorrasagasti C, Aquino JB, Hofman L, Alaniz L, Malvicini M, Garcia M, Benedetti L, Friedman SL, Podhajcer O, Mazzolini G.

Am J Physiol Gastrointest Liver Physiol. 2011 May;300(5):G739-48. doi: 10.1152/ajpgi.00316.2010. Epub 2011 Feb 10.

16.

A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice.

Malvicini M, Rizzo M, Alaniz L, Piñero F, García M, Atorrasagasti C, Aquino JB, Rozados V, Scharovsky OG, Matar P, Mazzolini G.

Clin Cancer Res. 2009 Dec 1;15(23):7256-65. doi: 10.1158/1078-0432.CCR-09-1861. Epub 2009 Nov 17.

17.

Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells.

Atorrasagasti C, Malvicini M, Aquino JB, Alaniz L, Garcia M, Bolontrade M, Rizzo M, Podhajcer OL, Mazzolini G.

Int J Cancer. 2010 Jun 1;126(11):2726-40. doi: 10.1002/ijc.24966.

18.

Immunotherapy for liver tumors: present status and future prospects.

Matar P, Alaniz L, Rozados V, Aquino JB, Malvicini M, Atorrasagasti C, Gidekel M, Silva M, Scharovsky OG, Mazzolini G.

J Biomed Sci. 2009 Mar 6;16:30. doi: 10.1186/1423-0127-16-30. Review.

19.

Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response.

Alaniz L, Rizzo M, Malvicini M, Jaunarena J, Avella D, Atorrasagasti C, Aquino JB, Garcia M, Matar P, Silva M, Mazzolini G.

Cancer Lett. 2009 Jun 8;278(1):9-16. doi: 10.1016/j.canlet.2008.12.029. Epub 2009 Jan 29.

PMID:
19185418
20.

Adenovirus-mediated inhibition of SPARC attenuates liver fibrosis in rats.

Camino AM, Atorrasagasti C, Maccio D, Prada F, Salvatierra E, Rizzo M, Alaniz L, Aquino JB, Podhajcer OL, Silva M, Mazzolini G.

J Gene Med. 2008 Sep;10(9):993-1004. doi: 10.1002/jgm.1228.

PMID:
18615449
21.

Immunotherapy and immunoescape in colorectal cancer.

Mazzolini G, Murillo O, Atorrasagasti C, Dubrot J, Tirapu I, Rizzo M, Arina A, Alfaro C, Azpilicueta A, Berasain C, Perez-Gracia JL, Gonzalez A, Melero I.

World J Gastroenterol. 2007 Nov 28;13(44):5822-31. Review.

22.

Trypanosoma cruzi: analysis of the complete PUF RNA-binding protein family.

Caro F, Bercovich N, Atorrasagasti C, Levin MJ, Vázquez MP.

Exp Parasitol. 2006 Jun;113(2):112-24. Epub 2006 Feb 7.

PMID:
16460732
23.

Protein interactions within the TcZFP zinc finger family members of Trypanosoma cruzi: implications for their functions.

Caro F, Bercovich N, Atorrasagasti C, Levin MJ, Vázquez MP.

Biochem Biophys Res Commun. 2005 Aug 5;333(3):1017-25.

PMID:
15964555
24.

Unique features of the Trypanosoma cruzi U2AF35 splicing factor.

Vázquez M, Atorrasagasti C, Bercovich N, Volcovich R, Levin MJ.

Mol Biochem Parasitol. 2003 Apr 25;128(1):77-81. No abstract available.

PMID:
12706799

Supplemental Content

Loading ...
Support Center